Javascript must be enabled to continue!
Indanones As High‐Potency Reversible Inhibitors of Monoamine Oxidase
View through CrossRef
AbstractRecent reports document that α‐tetralone (3,4‐dihydro‐2H‐naphthalen‐1‐one) is an appropriate scaffold for the design of high‐potency monoamine oxidase (MAO) inhibitors. Based on the structural similarity between α‐tetralone and 1‐indanone, the present study involved synthesis of 34 1‐indanone and related indane derivatives as potential inhibitors of recombinant human MAO‐A and MAO‐B. The results show that C6‐substituted indanones are particularly potent and selective MAO‐B inhibitors, with IC50 values ranging from 0.001 to 0.030 μM. C5‐Substituted indanone and indane derivatives are comparatively weaker MAO‐B inhibitors. Although the 1‐indanone and indane derivatives are selective inhibitors of the MAO‐B isoform, a number of homologues are also potent MAO‐A inhibitors, with three homologues possessing IC50 values <0.1 μM. Dialysis of enzyme–inhibitor mixtures further established a selected 1‐indanone as a reversible MAO inhibitor with a competitive mode of inhibition. It may be concluded that 1‐indanones are promising leads for the design of therapies for neurodegenerative and neuropsychiatric disorders such as Parkinson’s disease and depression.
Title: Indanones As High‐Potency Reversible Inhibitors of Monoamine Oxidase
Description:
AbstractRecent reports document that α‐tetralone (3,4‐dihydro‐2H‐naphthalen‐1‐one) is an appropriate scaffold for the design of high‐potency monoamine oxidase (MAO) inhibitors.
Based on the structural similarity between α‐tetralone and 1‐indanone, the present study involved synthesis of 34 1‐indanone and related indane derivatives as potential inhibitors of recombinant human MAO‐A and MAO‐B.
The results show that C6‐substituted indanones are particularly potent and selective MAO‐B inhibitors, with IC50 values ranging from 0.
001 to 0.
030 μM.
C5‐Substituted indanone and indane derivatives are comparatively weaker MAO‐B inhibitors.
Although the 1‐indanone and indane derivatives are selective inhibitors of the MAO‐B isoform, a number of homologues are also potent MAO‐A inhibitors, with three homologues possessing IC50 values <0.
1 μM.
Dialysis of enzyme–inhibitor mixtures further established a selected 1‐indanone as a reversible MAO inhibitor with a competitive mode of inhibition.
It may be concluded that 1‐indanones are promising leads for the design of therapies for neurodegenerative and neuropsychiatric disorders such as Parkinson’s disease and depression.
Related Results
Type B Monoamine Oxidase and Neurotoxins
Type B Monoamine Oxidase and Neurotoxins
The biochemical process underlying Parkinson’s disease is dopamine cell death of the nigrostriatal system. The age-dependent cell death is now proposed to be elicited by the format...
Therapeutic potential of SGLT-2 inhibitors and DDP4 inhibitors in elderly patients with type 2 diabetes mellitus and benign prostatic hyperplasia
Therapeutic potential of SGLT-2 inhibitors and DDP4 inhibitors in elderly patients with type 2 diabetes mellitus and benign prostatic hyperplasia
Background. Benign prostatic hyperplasia (BPH) has recently been linked to diabetes mellitus and insulin resistance. This study aims to explore whether the use of either sodium-glu...
The Effects of Xanthine Oxidase Inhibitors on the Management of Cardiovascular Diseases
The Effects of Xanthine Oxidase Inhibitors on the Management of Cardiovascular Diseases
Cardiovascular diseases (CVDs) are the fastest-growing cause of death around the world, and atherosclerosis plays a major role in the etiology of CVDs. The most recent figures show...
Efficacy and safety of neoadjuvant PD-1 inhibitors or PD-L1 inhibitors for muscle invasive bladder cancer: a systematic review and meta-analysis
Efficacy and safety of neoadjuvant PD-1 inhibitors or PD-L1 inhibitors for muscle invasive bladder cancer: a systematic review and meta-analysis
IntroductionThis meta-analysis aims to evaluate the efficacy and safety of neoadjuvant PD-1 inhibitors or PD-L1 inhibitors [PD-(L)1 inhibitors] for muscle-invasive bladder carcinom...
Aurone Scaffold and Structural Analogues for the Development of Monoamine Oxidase (MAO) Inhibitors
Aurone Scaffold and Structural Analogues for the Development of Monoamine Oxidase (MAO) Inhibitors
<div>Continuous efforts in the development of monoamine oxidase inhibitors</div><div>prompted the search for effective strategies for the design of novel drugs ca...
Inhibition of monoamine oxidase by selected phenylalkylcaffeine analogues
Inhibition of monoamine oxidase by selected phenylalkylcaffeine analogues
AbstractObjectivesCaffeine represents a useful scaffold for the design of monoamine oxidase (MAO) type B inhibitors. Specifically, substitution on the C8 position yields structures...
Dihydropyrimidines Emerge as Promising Dual‐Acting Inhibitors Targeting Acetylcholinesterase and Monoamine Oxidases for Alzheimer's and Other Neurological Disorders
Dihydropyrimidines Emerge as Promising Dual‐Acting Inhibitors Targeting Acetylcholinesterase and Monoamine Oxidases for Alzheimer's and Other Neurological Disorders
Abstract
The pathogenesis of Alzheimer's disease (AD) is multifaceted, and more than one factor is deemed responsible for its genesis and pro...
Controlling Ethylene Responses in Horticultural Crops at the Receptor Level
Controlling Ethylene Responses in Horticultural Crops at the Receptor Level
Ethylene is a plant hormone that controls many plant responses, such as growth, senescence, ripening, abscission and seed germination. Recently, 1-methy- cyclopropene (1-MCP), was ...

